A Phase 2/3, multicenter, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema

Abstract

To confirm the safety and compare the efficacy of intravitreal pegaptanib sodium 0,3mg versus sham injection in subject with diabetic macular edema (DME). 36,8% subjects from the pegaptanib group versus 19,7% subjects from the sham group experienced a VA improvement of 10 letters at week 54. At week 102, pegaptanib treated subjects gained, on average, 6,1 letters versus 1,3 letters for sham (P0,01).

These findings indicate that intravitreal pegaptanib is effective in the traetment of DME and has positive safety profile.

Keywords

• pegaptanib sodium
• diabetic macular edema